VRTX Stock Overview
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VRTX from our risk checks.
Vertex Pharmaceuticals Incorporated Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$372.25 |
52 Week High | US$416.85 |
52 Week Low | US$289.10 |
Beta | 0.37 |
1 Month Change | -0.73% |
3 Month Change | -7.63% |
1 Year Change | 25.44% |
3 Year Change | 104.76% |
5 Year Change | 140.53% |
Change since IPO | 253.60% |
Recent News & Updates
Recent updates
Shareholder Returns
VRTX | AT Biotechs | AT Market | |
---|---|---|---|
7D | 0.9% | -3.0% | -0.6% |
1Y | 25.4% | -12.4% | 1.8% |
Return vs Industry: VRTX exceeded the Austrian Biotechs industry which returned -12% over the past year.
Return vs Market: VRTX exceeded the Austrian Market which returned 2.6% over the past year.
Price Volatility
VRTX volatility | |
---|---|
VRTX Average Weekly Movement | 2.7% |
Biotechs Industry Average Movement | 7.7% |
Market Average Movement | 3.5% |
10% most volatile stocks in AT Market | 5.4% |
10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: VRTX has not had significant price volatility in the past 3 months.
Volatility Over Time: VRTX's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 5,400 | Reshma Kewalramani | www.vrtx.com |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
Vertex Pharmaceuticals Incorporated Fundamentals Summary
VRTX fundamental statistics | |
---|---|
Market cap | €96.64b |
Earnings (TTM) | €3.41b |
Revenue (TTM) | €9.29b |
28.4x
P/E Ratio10.4x
P/S RatioIs VRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VRTX income statement (TTM) | |
---|---|
Revenue | US$9.87b |
Cost of Revenue | US$4.43b |
Gross Profit | US$5.44b |
Other Expenses | US$1.82b |
Earnings | US$3.62b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
Earnings per share (EPS) | 14.00 |
Gross Margin | 55.16% |
Net Profit Margin | 36.68% |
Debt/Equity Ratio | 0% |
How did VRTX perform over the long term?
See historical performance and comparison